{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:14:09Z","timestamp":1780535649172,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.amjcard.2009.10.009","type":"journal-article","created":{"date-parts":[[2009,12,19]],"date-time":"2009-12-19T04:09:08Z","timestamp":1261195748000},"page":"30A-35A","source":"Crossref","is-referenced-by-count":79,"special_numbering":"S","title":["Renin\u2013Angiotensin System Blockade and Cardiovascular and Renal Protection"],"prefix":"10.1016","volume":"105","author":[{"given":"Byron J.","family":"Hoogwerf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2009.10.009_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.10.009_bib2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jash.2007.04.004","article-title":"Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis","volume":"1","author":"Weir","year":"2007","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.amjcard.2009.10.009_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","article-title":"Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 \u2013 BHS-IV","volume":"18","author":"Williams","year":"2004","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.amjcard.2009.10.009_bib4","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1016\/S0895-7061(01)02275-0","article-title":"Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?","volume":"15","author":"Pitt","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjcard.2009.10.009_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ahj.2004.04.037","article-title":"Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"148","author":"Kjeldsen","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2009.10.009_bib6","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","article-title":"Renin-angiotensin system and cardiovascular risk","volume":"369","author":"Schmieder","year":"2007","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1016\/j.amjcard.2009.10.009_bib7","first-page":"S14","article-title":"Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy","volume":"8","author":"Giles","year":"2007","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2009.10.009_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.10.009_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.10.009_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2009.10.009_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2009.10.009_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2009.10.009_bib13","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.10.009_bib14","first-page":"S161","article-title":"Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II","volume":"45","author":"Ravid","year":"1994","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.amjcard.2009.10.009_bib15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.10.009_bib16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.10.009_bib17","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.10.009_bib18","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc06-1998","article-title":"Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes","volume":"30","author":"Makino","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2009.10.009_bib19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1291\/hypres.31.657","volume":"31","author":"Makino","year":"2008","journal-title":"Hypertension Res"},{"key":"10.1016\/j.amjcard.2009.10.009_bib20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","article-title":"Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy","volume":"74","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2009.10.009_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2009.10.009_bib22","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2009.10.009_bib23","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.10.009_bib24","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.10.009_bib25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jacc.2005.09.055","article-title":"The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)","volume":"47","author":"McMurray","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.10.009_bib26","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1592\/phco.26.9.1297","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis","volume":"26","author":"McCall","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjcard.2009.10.009_bib27","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","article-title":"Ramipril and the development of diabetes","volume":"286","author":"Yusuf","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2009.10.009_bib28","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1161\/CIRCULATIONAHA.105.548461","article-title":"Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE Study extension","volume":"112","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.10.009_bib29","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes","volume":"355","year":"2006","journal-title":"N Engl J Med"},{"issue":"suppl 1A","key":"10.1016\/j.amjcard.2009.10.009_bib30","doi-asserted-by":"crossref","first-page":"10A","DOI":"10.1016\/j.amjcard.2009.10.006","article-title":"Progression of cardiovascular damage: the role of renin\u2013angiotensin system blockade","author":"Probstfield","year":"2010","journal-title":"Am J Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914909024849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914909024849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T07:23:57Z","timestamp":1544772237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914909024849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0002914909024849"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2009.10.009","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}